OpGen sells Unyvero customer contracts to Camtech for $218k; plans exit from Unyvero business

CapForce Inc.

Sale of Unyvero customer contracts and installed base to Camtech Pte Ltd for $218,000, closing expected May 2024.
OpGen offered Camtech option to purchase remaining Unyvero inventory for up to $176,000; will maintain support until then.
Subsidiary Ares Genetics sold all assets (ARESdb, IP) to bioMerieux as part of insolvency proceedings.
CEO states transactions prepare OpGen for potential strategic alternative, including reverse merger with a private company.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CapForce Inc. entered into Agreement with Camtech Pte Ltd valued at $218,000 (effective 2024-04-23).

Action: entry
Agreement: asset purchase
Counterparty: Camtech Pte Ltd
Value: $218,000
Effective: 2024-04-23

Exact text from the filing

On April 23, 2024, OpGen, Inc. (the “Company”) entered into a letter agreement (the “Agreement”) with Camtech Pte Ltd, a Singaporean family office (“Camtech”), for the sale of certain of the Company’s inventory and customer contracts for its Unyvero products.

View on SEC.gov

Browse all material agreements →

Source: SEC EDGAR

accession 0001829126-24-002907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.